Zhuang Xieyan, Li Yan, Zheng Hongfeng, Fu Langjing
Gynecology Department of Mingzhou Hospital, Ningbo, Zhejiang, China.
Front Oncol. 2024 Dec 23;14:1461175. doi: 10.3389/fonc.2024.1461175. eCollection 2024.
Recently, the neutrophil-to-lymphocyte ratio (NLR) has emerged as a promising prognostic marker for survival outcomes in individuals affected cervical cancer. However, research specifically focusing on the prognostic relevance of NLR across different cancer stages and in cases of recurrent metastases remains scant.
We executed a systematic review of the literature from databases including PubMed, Embase, the Cochrane Library, and Web of Science, covering publications up to March 3, 2024. Studies evaluating the relationship between NLR and patient clinical outcomes were retrieved, guided by specifically defined inclusion and exclusion parameters. The key goals were to assess progression-free survival (PFS) and overall survival (OS), measured through hazard ratios (HR) and 95% confidence intervals (CI).
This meta-analysis encompassed 38 retrospective cohort studies, including data from 10,246 patients. The aggregated data showed that patients with increased NLR prior to treatment exhibit reduced OS (HR = 1.58, 95% CI: 1.44-1.74; p < 0.00001) and decreased PFS (HR = 1.48, 95% CI: 1.34-1.63; p < 0.00001). Furthermore, elevated NLR significantly impacted disease-free survival (HR: 1.79, 95% CI: 1.18-2.71; p = 0.006), recurrence rates (HR: 2.18, 95% CI: 1.36-3.51; p = 0.001), recurrence-free survival (HR: 3.05, 95% CI: 1.79-5.19; p < 0.0001), and the incidence of distant metastases (HR: 1.73, 95% CI: 1.20-2.50; p = 0.003).
An elevated NLR prior to treatment demonstrates a strong association with decreased OS and PFS among patients with cervical cancer, underscoring the significance of NLR as a prognostic marker within this population.
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=529817, identifier CRD42024529817.
最近，中性粒细胞与淋巴细胞比值（NLR）已成为宫颈癌患者生存结局的一个有前景的预后标志物。然而，专门针对不同癌症阶段以及复发转移情况下NLR的预后相关性的研究仍然很少。
我们对包括PubMed、Embase、Cochrane图书馆和Web of Science在内的数据库中的文献进行了系统综述，涵盖截至2024年3月3日的出版物。在明确定义的纳入和排除参数的指导下，检索评估NLR与患者临床结局之间关系的研究。主要目标是通过风险比（HR）和95%置信区间（CI）评估无进展生存期（PFS）和总生存期（OS）。
这项荟萃分析包括38项回顾性队列研究，涉及10246例患者的数据。汇总数据显示，治疗前NLR升高的患者总生存期降低（HR = 1.58，95% CI：1.44 - 1.74；p < 0.00001），无进展生存期降低（HR = 1.48，95% CI：1.34 - 1.63；p < 0.00001）。此外，NLR升高对无病生存期（HR：1.79，95% CI：1.18 - 2.71；p = 0.006）、复发率（HR：2.18，95% CI：1.36 - 3.51；p = 0.001）、无复发生存期（HR：3.05，95% CI：1.79 - 5.19；p < 0.0001）和远处转移发生率（HR：1.73，95% CI：1.20 - 2.50；p = 0.003）有显著影响。
治疗前NLR升高表明与宫颈癌患者的总生存期和无进展生存期降低密切相关，强调了NLR作为该人群预后标志物的重要性。
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=529817，标识符CRD42024529817。
